Biote Q2 2026 revenue $44.2M (-9.5% YoY); net loss $(7.4)M vs net income $3.9M; updates full-year outlook

biote Corp.

Revenue $44.2M (-9.5% YoY); procedure revenue $30.3M (-13.9%) due to voluntary recall of Asteria Health pellets.
Net loss $(7.4)M ($0.23 diluted loss per share) vs net income $3.9M ($0.10 EPS) in Q2 2025.
Adjusted EBITDA $5.6M (12.6% margin); gross margin 65.4% vs 71.6% due to recall costs.
Dietary supplements revenue grew 5.7% to $11.4M.
Company updated full-year 2026 outlook; specifics not provided in excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.